BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 24384911)

  • 1. Androgen receptor signaling in prostate cancer.
    Culig Z; Santer FR
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):413-27. PubMed ID: 24384911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.
    Culig Z; Santer FR
    Steroids; 2013 Sep; 78(9):851-9. PubMed ID: 23643785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD; Lambert JR; Nordeen SK
    Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
    Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
    Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collocation of androgen receptor gene mutations in prostate cancer.
    Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
    Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification and co-regulators of androgen receptor gene in prostate cancer.
    Golias Ch; Iliadis I; Peschos D; Charalabopoulos K
    Exp Oncol; 2009 Mar; 31(1):3-8. PubMed ID: 19300409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
    Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy.
    Burnstein KL
    J Cell Biochem; 2005 Jul; 95(4):657-69. PubMed ID: 15861399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor in prostate cancer.
    Heinlein CA; Chang C
    Endocr Rev; 2004 Apr; 25(2):276-308. PubMed ID: 15082523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
    Agoulnik IU; Weigel NL
    J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development.
    Moehren U; Papaioannou M; Reeb CA; Grasselli A; Nanni S; Asim M; Roell D; Prade I; Farsetti A; Baniahmad A
    FASEB J; 2008 Apr; 22(4):1258-67. PubMed ID: 17991730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
    Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
    Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
    McCarty MF; Hejazi J; Rastmanesh R
    Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.